Last updated on September 2018

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Brief description of study

This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy. Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study treatment.

Clinical Study Identifier: NCT02232633

Contact Investigators or Research Sites near you

Start Over

Vincent Tam, MD

University of Calgary
Calgary, AB Canada

Saara Ali

The Ottawa Hospital Cancer Centre
Ottawa, ON Canada

Jennifer Knox, MD

Princess Margaret Hospital
Toronto, ON Canada